Dr. Illei’s research focuses on the immunohistochemichal and molecular characterization of lung cancers and mesothelioma.
Illei PB, Wong W, Wu N, Chu L, Gupta R, Schulze K, Gubens MA. ALK Testing Trends and Patterns Among Community Practices in the United States. JCO Precision Oncol. Epub Oct. 8, 2018.
Xing D, Banet N, Sharma R, Vang R, Ronnett BM, Illei PB. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study. Hum Pathol. 2017 Dec 11. [Epub ahead of print]
Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haly L, Riel S, Beierl K, Zheng G, Brahmer JR, Askin FB, Gocke CD, Eshleman JR, Forde PM and Ling MT. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget. 5/20/2017 [Epub ahead of print].
Illei PB, Rusch V, Zakowski MF, Ladanyi M: Homozygous Deletion of CDKN2A and Co-Deletion of the Methylthioadenosine Phosphorylase Gene in the Majority of Pleural Mesotheliomas. Clin Can Res. 2003 Jun;9(6):2108-13.
Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010 Jan;41(1):20-5. Epub 2009 Sep 8.